PERSONALIZED GENE THERAPY TREATMENTS FOR CANCER MARKET ANALYSIS

Gene therapy involves insertion of genetic material into cells of the patients to provide them a new function or to restore the missing or inappropriate functioning of the cells due to cancer or gene mutations. Scientists have created personalized medicines that are used to learn about a person’s genetic makeup and untangle the biologic nature of the patient’s cancerous cells for carrying out such therapies. Depending on the type of therapy, personalized gene therapy treatments for cancer market is differentiated into two segments which are as follows:

• Targeted treatments
• Pharmacogenomics

On the basis of application, the personalized gene therapy treatments for cancer market is analyzed into:

• Breast Cancer
• Leukemia
• Head & Neck Cancer
• Prostate Cancer
• Pancreatic Cancer
• Leukemia Cancer
• Melanoma
• Ovarian Cancer
• Brain Cancer
• Colorectal Cancer
• Lung Cancer
• Liver Cancer
• Bladder Cancer
• Lymphoma

Personalized Gene Therapy Treatments for Cancer Market Potential Applications

Targeted treatments are focused on cancer specific genes, tissues or the protein environment that contribute towards the cancer survival and growth. Researchers identify new targeted cells and develop and test new drugs and medications for such targets as per patient needs. In targeted treatments, the tumor cells themselves are targeted to cure cancer. Breast cancer, gastrointestinal stromal tumor, colorectal cancer, kidney cancer, melanoma, lung cancer, brain cancer, multiple myeloma, certain childhood cancers and lymphoma, and leukemia are the common types of cancers for which targeted treatments are applied.

Pharmacogenomics, on the other hand, affect the processes occurring in the body and drug responses. The difference in the processes influences the safety and efficacy of a drug. The basic principle behind the treatment is to activate the immune system cells that could attack and destroy the cancerous cells. Moreover, in this case, if the patients’ body does not respond to a medication, the drugs stay in the blood stream for longer period of time and may cause severe side effects. Therefore, this type of treatment carries a risk of reaction of drug from person to person, providing targeted treatment a preference over pharmacogenomics.

Personalized gene therapy treatments for cancer market involves evaluation of the developed drugs through clinical trials. Government support and funding and the advantages of personalized gene therapy over other treatment options such as chemotherapy and surgery are the major factors which are projected to drive growth of personalized gene therapy treatments for cancer market. For instance, the U.S. government has set up the MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy in Texas to support preclinical research and clinical trials for targeted therapy for particular genes. Such government initiatives are encouraging researchers to develop more effective personalized gene therapy treatments for different types of cancer, thus boosting growth of the cancer personalized gene therapy treatments market. However, high costs associated with these treatments and the unavailability of personalized gene therapy treatment for some types of cancers is the major factor that is projected to restrain growth of the personalized gene therapy treatments for cancer market.

Geographically, the personalized gene therapy treatments for cancer market has been analyzed into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The major players in the customized gene therapy treatments for cancer market include Amgen, Inc., SynerGene Therapeutics, Inc., Chengdu Shi Endor Biological Engineering Technology Co., Ltd., Cold Genesys, Inc., Takara Bio, Inc., Bellicum Pharmaceuticals, Inc., Ziopharm Oncology, Inc., OncoSec Medical, Inc., Sevion Therapeutics, Inc., and Burzynski Clinic.

Key Developments

Major government bodies and NGOs are focused on supporting R&D in personalized gene therapies for cancer. For instance, in August 2019, The National Cancer Institute of the National Institutes of Health (US) awarded Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis with a US$ 15 million grant in a research to investigate the genetic changes that cause acute myeloid leukemia.

Similarly, in August 2019, The Leukemia & Lymphoma Society (LLS) increased pediatric cancer research funding through US$ 50 million Children’s Initiative by adding 20 new grants valued at over US$ 13.8 million to its 2019 portfolio. The LLS aims for the treatment of leukemia & lymphoma patients with multiple targeted therapies simultaneously at up to 200 clinical sites worldwide.

Major institutes are focused on R&D of novel approaches in personalized gene therapies for cancer. For instance, in August 2019, researchers from the Institute of Cancer Research, London, reported use of Artificial Intelligence and Machine Learning to identity five new subtypes of breast cancer. The development reported in the journal NPJ Breast Cancer is expected to aid in development of personalized diagnostics and gene therapies.